Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Yuki Iwaki"'
Autor:
Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz‐Guiñazú, Juan José Pérez‐Ruixo
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1485-1498 (2023)
Abstract Mechanistic model‐based simulations can be deployed to project the persistence of humoral immune response following vaccination. We used this approach to project the antibody persistence through 24 months from the data pooled across five c
Externí odkaz:
https://doaj.org/article/e5c516261c6749c5aae3b158bce0490e
Autor:
Hiroji Uemura, Yosuke Koroki, Yuki Iwaki, Keiichiro Imanaka, Takeshi Kambara, Angela Lopez-Gitlitz, Andressa Smith, Hirotsugu Uemura
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background A higher incidence of apalutamide-related skin rash has been observed in Japanese patients with prostate cancer (PC). Methods This integrated analysis of data of Japanese patients from 2 global Phase 3 studies, SPARTAN ( NCT019462
Externí odkaz:
https://doaj.org/article/a80c9a58c8bb42bd88c5181464556d26
Autor:
Hiroji Uemura, Yosuke Koroki, Yuki Iwaki, Keiichiro Imanaka, Takeshi Kambara, Angela Lopez-Gitlitz, Andressa Smith, Hirotsugu Uemura
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-2 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/84be7818791645b9b080480c1ace7401
Publikováno v:
Journal of clinical pharmacology.
The population pharmacokinetic (PK) and exposure-response (E-R) analyses for safety of ibrutinib for the treatment of chronic graft-versus-host disease (cGVHD) is presented. This work aims to develop a population PK model for ibrutinib based on data
Autor:
Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Raluca Verona, Lixia Pei, Yaming Su, Daniele Ouellet, Alfred L. Garfall, Amrita Y. Krishnan, Saad Usmani, Suzette Girgis, Honghui Zhou
Publikováno v:
Blood. 140:4382-4383
Autor:
Dean F. Rigel, Gary M. Coppola, Frederic Villard, Li Fan, Muneto Mogi, Emma Cody, Nikolaus Schiering, Guiqing Liang, Christian Wiesmann, Arco Y. Jeng, Yongjin Gong, Jing Liu, Paul Ramage, Fumin Fu, Alan D. Neubert, Yuki Iwaki, Allan D'Arcy, Qian Liu, Wei Chen, Jennifer Leung-Chu, Robert Sun, Rajeshri Ganesh Karki, Frederic Cumin, Toshio Kawanami, Gary Michael Ksander, Sara Ingles, Michael E. Beil
Publikováno v:
ACS Med Chem Lett
[Image: see text] Inhibition of neprilysin (NEP) is widely studied as a therapeutic target for the treatment of hypertension, heart failure, and kidney disease. Sacubitril/valsartan (LCZ696) is a drug approved to reduce the risk of cardiovascular dea
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 15:897-911
Introduction: Statins are prescribed widely for cholesterol-lowering therapy, but it is known that their efficacy and safety profiles vary, despite the shared pharmacophore and pharmacological target. The immense body of related clinical and preclini
Publikováno v:
Journal of clinical pharmacologyReferences. 62(2)
Guselkumab is a human IgG1λ monoclonal antibody that has been approved for treatment of multiple immunological diseases including palmoplantar pustulosis (PPP) in Japan. The efficacy of guselkumab in reducing disease severity as compared with placeb
Autor:
Dean F. Rigel, Hidetomo Imase, Kayo Yasoshima, Darcy Kohls, Toshio Kawanami, Yukiko I. Yagi, Jun Yuan, Monish Jain, Hyi-Man Park, Upendra A. Argikar, David Yowe, Paul Taslimi, Xiaoling Xie, Yuki Iwaki, Neeraja Idamakanti, Taeyong Yoon, Ken Yamada, Vidya Kunjathoor, Keith DiPetrillo, Lingfei Xu, Mitsunori Kato, Meicheng Zhu, Julian Levell, Zachary Robinson, Lauren G. Monovich
Publikováno v:
Journal of Medicinal Chemistry. 60:7099-7107
The observed structure-activity relationship of three distinct ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor series, together with a crystal structure of a previously disclosed allosteric inhibitor bound to WNK1, led to an overlay hypothes
Autor:
Akito Yamaguchi, Yuki Iwaki, Hiroji Uemura, Tomohiro Tsuchiya, Ryo Oyama, Keiichiro Imanaka, Katsuyoshi Hashine
Publikováno v:
International Journal of Clinical Oncology
Background Apalutamide, a nonsteroidal potent androgen receptor antagonist, was safe and effective in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic-CRPC (mCRPC) in global studies. In this phase 1 study, saf